Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058214 · ClinicalTrials.gov registry record · Phase 2
Perifosine in Treating Patients With Recurrent Prostate Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00058214: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00058214 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00058214, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of perifosine in treating patients who have recurrent prostate cancer. Drugs used in chemotherapy such as perifosine use different ways to stop tumor cells from dividing so they stop growing or die
Interventions
- OTHER laboratory biomarker analysis
- DRUG perifosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2003-03 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00058214
The ClinicalTrials.gov registry entry for NCT00058214 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00058214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00058214 about?
NCT00058214 is a clinical study titled "Perifosine in Treating Patients With Recurrent Prostate Cancer". Phase II trial to study the effectiveness of perifosine in treating patients who have recurrent prostate cancer. Drugs used in chemotherapy such as perifosine use different ways to stop tumor cells from dividing so they stop growing or die
What is the current status of trial NCT00058214?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2003-03. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00058214?
The interventions under investigation include: laboratory biomarker analysis (OTHER), perifosine (DRUG).
Who is sponsoring clinical trial NCT00058214?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.